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Background/Objectives: To predict the health economic consequences of modest reductions in the daily intake of salt
( 1.0g per day) and replacement of saturated fat (SFA,  1.0 energy percent (E%)) with polyunsaturated fat (PUFA, þ1.0 E%)
in the Finnish population aged 30–74 years.
Subjects/Methods: A Markov model with dynamic population structure was constructed to present the natural history of
cardiovascular diseases (CVDs) based on the most current information about the age- and sex-specific cardiovascular risk factors,
dietary habits and nutrient intake. To predict the undiscounted future health economic consequences of the reduction of dietary
salt and SFA, the model results were extrapolated for the years 2010–2030 by replacing the baseline population in the year 2007
with the extrapolated populations from the official Finnish statistics. Finnish costs (h2009, societal perspective) and EQ-5D
utilities were obtained from published references.
Results: During the next 20 years, a population-wide intervention directed at salt intake and dietary fat quality could potentially
lead to 8000–13000 prevented CVD cases among the Finnish adults compared the situation in year 2007. In addition, the
reduced incidence of CVDs could gain 26000–45000 quality-adjusted life years and save h150–225 million over the same time
period.
Conclusion: A modest reduction of salt and replacement of SFA with PUFA in food products can significantly reduce the burden
of CVD in the adult Finnish population. This impact may be even larger in the near future due to the ageing of Finnish
population.
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Introduction
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in industrialised countries, causing
high health care utilisation costs. Elevated systolic blood
pressure (SBP), total cholesterol (TC) and smoking are the
best known major risk factors of CVD (Vartiainen et al.,
2010). SBP (4115mmHg) is the single most important cause
responsible for 460% of strokes and B50% of coronary
heart disease events, whereas corresponding figures for
elevated TC (43.8mmol/l) are around 20% and 450%,
respectively (World Health Report, 2002).
The population-wide reduction in dietary salt and replace-
ment of dietary saturated fat (SFA) with polyunsaturated fat
(PUFA) are essential in reducing CVD incidence. Their
importance is mediated at least in part by the effect of salt
on blood pressure (BP) and dietary fat quality on total and
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www.nature.com/ejcnlow-density lipoprotein cholesterol. The risk of CVD events
increases progressively with increasing BP and cholesterol.
The major portion of CVD deaths attributable to BP and
cholesterol occurs in the upper range of ‘normal’ BP and TC
levels (that is, BP 4130/80mmHg and TC 43.8mmol/l; He
and MacGregor, 2009).
In Finland, around 75% of the observed decline in
coronary mortality in middle-aged men can be explained
by decreases in BP, TC and smoking (Vartiainen et al., 2010).
Even though public health interventions aimed at these
risk factors have dramatically decreased CVD disability and
deaths in developed countries (He and MacGregor, 2009),
CVD is still the most common cause of death, and stroke
and acute myocardial infarction (MI) are major causes of
disability. Despite marked changes in diet since the 1970s,
average dietary intake of salt (8.4g per day and 6.1g per day
for men and women, respectively) and SFA (12.7 E% per
day for both sexes) are still above recommended levels (o5g
per day and o10 E%), with relatively low PUFA intake (World
Health Organisation, 2007; Paturi et al., 2008). Therefore,
modest reduction of dietary salt and improvement of dietary
fat quality, with even small shifts in the population distribu-
tions of SBP and TC towards lower values, may improve the
health economic consequences of CVD substantially.
No detailed analyses on the economic consequences of
reducing dietary salt and improving dietary fat quality intake
have been carried out in the adult Finnish population. This
study aims to predict the potential health economic
consequences of moderate reduction of dietary salt com-
bined with replacing some dietary SFA by PUFA. Owing to
the data limitations, the analysis was restricted to Finns aged
30–74 years.
Subjects and methods
The year 2007 was selected as the baseline year for the
CVD risk factors. A previously developed state transition
Markov cohort model (Figure 1) for coronary heart disease
(Martikainen et al., 2007; Peura et al., 2008) was enhanced by
adding stroke and population components (Mar et al., 2008).
The new model was applied to estimate the incidence and
prevalence of CVD events and mortality, impact on quality
of life and associated costs in the adult Finnish population.
First, the most current available national risk factor survey
data (Peltonen et al., 2008) and CVD risk functions
(Vartiainen et al., 2007) were incorporated into the Markov
model. Second, an additional model component (Mar et al.,
2008) was built into the Markov model to estimate the total
number of CVD patients in the Finnish population in 2007,
and to make predictions for the years 2010–2030. Population
estimates for adults aged X30 in year 2007 and population
projections for years 2010–2030 were obtained from the
official Finnish statistics. To predict the effects of risk-redu-
cing interventions, expected numbers of events were extra-
polated for the years 2010–2030 using the corresponding
annual extrapolated populations from Finnish statistics. All
analyses were implemented in Microsoft Excel.
Event probabilities
For each 1-year cycle, the hypothetical cohort of men or
women without established CVD were at risk of having of an
acute non-fatal CVD event, a fatal CVD event, a fatal non-
CVD event, or they might survive to the next year without
suffering any event. The annual probabilities for CVD events
were determined by logistic risk functions based on the
FINRISK study (Vartiainen et al., 2007). After each cycle, CVD
risk factors were updated based on the Finnish age- and sex-
specific risk factor profile data from the FINRISK 2007 survey
(Peltonen et al., 2008). As the FINRISK risk functions are
developed to predict total CVD risk, information from the
National Cardiovascular Disease Register (Laatikainen et al.,
2004) was used to determine the age- and gender-based case
fatality. Annual risks of non-CVD deaths were estimated
from the causes of death register by subtracting fraction of
deaths due to CVDs from the total mortality. A more detailed
description of the methods used to estimate the event
probabilities is given in appendix.
The model was run until all subjects in the cohort entered
into terminal states or until 75 years of age was reached.
Because the FINRISK 2007 survey (Peltonen et al., 2008) and
its ancillary study FINDIET 2007 survey (Paturi et al., 2008)
did not include information about the levels of CVD risk
factors for people aged 75 years and older, the target
population was restricted to Finnish adults aged 30–74 to
ensure the reliability of the model outcomes.
Health care resource use and costs
Costs, estimated from a societal perspective, included direct
cost of prevention, morbidity, rehabilitation and production
losses due to non-fatal CVD events. All costs were adjusted to
Healthy Death
MI
(one cycle only)
History
of MI
History
of stroke
Stroke
(one cycle only)
Figure 1 Simplified structure of state transition model. The model
included five health states and death, which was modelled as an
absorbing terminal state. The ‘healthy’ state includes subjects
without a history of myocardial infarction (MI) or stroke, and they
have an annual probability of experiencing an initial non-fatal CVD
event (MI or stroke), fatal event (non-CVD death or CVD death) or
no CVD event.
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determined by the Association of Finnish Local and Regional
authorities. All costs were also predicted as future financial
streams over time to reflect the actual amount that the
reduction of SFA and salt intake can be expected to save in a
given year (Mauskopf et al., 2007; Marshall et al., 2008).
Annual age- and sex-specific costs (including costs of
hospitalisation, outpatient care and prescribed outpatient
medicines) associated with CVD events were obtained from
reports based on the national discharge and prescription
registries (Ha ¨kkinen et al., 2007; Meretoja et al., 2010). The
model assumes that, after hospital discharge, subjects
received a prescription for chronic coronary heart disease,
dyslipidaemia or hypertension. Average drug treatment costs
were weighted by the proportion of subjects receiving
reimbursement for those medicines.
Costs of CVD rehabilitation were estimated by weighting
the average rehabilitation costs obtained from the national
rehabilitation registry at the Social Insurance Institution of
Finland by the proportion (30–40%) of CVD patients
receiving rehabilitation. Productivity losses due to non-fatal
CVD events were estimated by multiplying the average
length of sickness leave due to MI (4.78 months; Vehvila ¨inen
et al., 2004) and stroke (8.11 months; Vohlonen et al., 2002)
by the average monthly income in Finland including payroll
tax. Productivity losses were applied to patients below the
average age of retirement, assumed to be 65 years. All unit
cost estimates are summarised in Table 1.
Quality-adjusted life years
Age- and sex-specific quality of life estimates measured by
generic EQ-5D instrument were used represent the average
quality of life in the Finnish population aged 30–75 (Saarni
et al., 2006). The disutility weights due to initial or
subsequent CVD events were determined from previously
published studies (Saarni et al., 2006; Lindgren et al., 2007;
Soini et al., 2010).
Estimating the effectiveness of reduced salt and SFA intake on the
number of CVD events and other outcomes
The reduction of 1g of salt per day was assumed to change
SBP approximately by  1.185mmHg among hyperten-
sive subjects and by  0.595mmHg among normotensive
subjects. These changes were estimated based on a dose–
response relationship between the changes in dietary salt
intake, 24-h urinary sodium and BP (He and MacGregor,
2003). These effect estimates were weighted by the age- and
sex-specific proportions of hypertensive subjects (SBP 4130)
in the Finnish population (Peltonen et al., 2008). The effect
of salt reduction on SBP was assumed to be linear over the
range of 0–3g per day (He and MacGregor, 2003).
Effects on serum TC of replacing SFA with PUFA were
obtained from a meta-analysis of metabolic ward studies
(Clarke et al., 1997). Every 1% increase in energy (E%) from
PUFA intake was expected to lead to a  0.026mmol/l change
in TC and 0.005mmol/l increase in high-density lipoprotein.
Alternatively, the predicted changes in serum cholesterol
were estimated by the Keys equation (Keys et al., 1957),
where 1 E% increase from PUFA was expected lead to around
 0.043mmol/l reduction in TC. The effect of changing BP
and cholesterol levels on CVD events and deaths was then
estimated using the FINRISK risk functions (Vartiainen et al.,
2007). To simplify the analysis, the full effect of dietary salt
and SFA reduction was assumed to be achieved immediately
and to persist during the whole time horizon.
Finally, the proportion of subjects receiving antihyperten-
sive medication was assumed to change as a function of SBP.
On the basis of an estimated logistic regression model, the
reduction of 1mmHg in SBP reduced the probability of
receiving antihypertensive medication with adjustment for
age, sex and body mass index, by B1.5% in men and 2.8% in
women (data on file).
Model calibration and sensitivity analyses
The model was calibrated to reproduce the number of key
cardiovascular events among the 30–74 years old population
in year 2007 in Finland. In addition, uncertainty associated
with the model parameters was handled by determining
probability distributions for all relevant parameters and then
conducting probabilistic sensitivity analysis with 1000
iteration rounds (Briggs et al., 2002). The selection of proper
probability distributions for the model parameters has been
described in details in technical appendix. The results of the
probabilistic sensitivity analysis were used to determine 95%
credibility intervals for the model outcomes and the
probability of savings as a function of amount of savings.
One-way sensitivity analyses were used to test the robustness
of model assumptions.
Results
The model was calibrated by comparing the model results to
the actual number of patient in the different health states in
the year 2007. For example, according to the FINRISK 2007
study, the prevalence of people with history of stroke and
MI is between 59900–68800 and 53800–63300 individuals
among the Finnish population aged 30–74 years old,
respectively (Peltonen et al., 2008). The calibrated model
estimated that the number of people with history of stroke is
around 61100 and the number of people with history of
MI is B58300. Thus, on average, the calibrated model was
considered to be sufficiently accurate to reproduce the
baseline population for the year 2007.
Over 20 years, a population-wide intervention could
potentially prevent 8000–13000 CVD cases among the
Finnish adults aged 30–74 compared with the status quo
scenario, where the CVD risk factors stay at the year 2007
levels over time. In addition, the reduced incidence of CVD
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adjusted life years and save 150–225 million Euros over the
same time period. Detailed results of base case and additional
one-way sensitivity analyses are presented in Table 2. Owing
to the linearity assumption of effects, the approximations of
outcomes with different reduction levels are easily extra-
polated based on the results presented in Table 2. For
example, reducing the daily intake of both dietary salt and
SFA by 0.5U would lead to around 74–113 million Euros
savings during the next 20 years.
To take the uncertainty of model parameters into account,
the probability of obtained cumulative savings was esti-
mated. Figure 2 shows that in the base case scenario there is
495% chance that the cumulative total savings with and
without productivity losses are at least 130 and 115 million
Euros between the years 2010 and 2030, respectively. In
addition, sensitivity analyses showed that the independent
effect of salt reduction in the prevention of cardiovascular
events is larger than the effect of replacing SFA by PUFA
(Table 2). The reduction of dietary salt is explained by 499%
of changes in the incidence of CVD events and their
consequences. However, when the Keys equation was used
to predict the changes in TC, the reduction of dietary salt
explained only around 62% the changes in the number of
CVD cases. Thus, the interpretation of results needs to be
carried out with care, as the results are sensitive to the
selection of effect size estimates.
Discussion
Main findings of the study
This study demonstrated that even a modest reduction of
dietary salt and replacement of dietary SFA with PUFA would
have a great impact on the incidence of CVD events among
the population aged 30–74 years. The lower number of CVD
Table 1 Parameters used in the model
a
Point estimate Source
Men Women
Utilities, mean (s.e.) Estimated based on Saarni et al. (2006)
and Soini et al. (2010) 30–44 0.917 (0.003) 0.906 (0.003)
45–54 0.876 (0.005) 0.865 (0.005)
55–64 0.821 (0.006) 0.810 (0.006)
65–74 0.781 (0.008) 0.770 (0.008)
Disutility due to CVD event, mean (s.e.)
Stroke  0.145 (0.097) Lindgren et al. (2007)
AMI  0.092 (0.029) Soini et al. (2010)
Post stroke  0.090 (0.020) Saarni et al. (2006)
Post MI  0.011 (0.009) Saarni et al. (2006)
Costs, mean (s.e.)
Stroke, mean (s.e.)
b 23240h Meretoja et al. (2010)
AMI
30–44 16245h (762) 16215h (760) Ha ¨kkinen et al. (2007)
45–54 14955h (701) 17503h (820)
55–64 14446h (677) 16326h (765)
65–74 12995h (609) 14958h (701)
Fatal AMI
c 2294h Hujanen et al. (2008)
Rehabilitation after stroke (first year) 6182h Assumption based on information
from SII’s database
Rehabilitation after MI (first year) 2576h Assumption based on information
from SII’s database
Antihypertensive medication in the primary
prevention per year
314 302
Dyslipidaemia therapy in the primary
prevention per year
195 166
Monitoring a patient receiving
antihypertensive medication
224h Assumption based on SII data
Monitoring a patient receiving statins 185h Assumption based on SII data
Monitoring a patient in secondary prevention 388h Assumption based on SII data
Productivity loses due to non-fatal stroke 11700h Vohlonen et al. (2002)
Productivity loses due to non-fatal MI 6884h Vehvila ¨inen et al. (2004)
Abbreviations: AMI, acute myocardial infarction; CVD, cardiovascular disease; MI, myocardial infarction; SII, Social Insurance Institution of Finland (Kela).
aCosts are presented in year 2009 values.
bEstimate is a weighted average cost of treatment of ischemic stroke (79.4%), subarachnoid haemorrhage (13.6%) and intracerebral haemorrhage (7%).
cA patient died during a hospitalisation.
Consequences of reducing salt and improving dietary fat quality
JA Martikainen et al
1151
European Journal of Clinical Nutritionevents would result in substantial gains in quality-adjusted
life years and cost savings.
The results of this study agree with previous studies
(Selmer et al., 2000; Murray et al., 2003; Bibbins-Domingo
et al., 2010; Smith-Spangler et al., 2010) that have demon-
strated the potential benefits of salt reduction to reduce the
burden of CVD. However, none of these previous studies
have directly estimated the joint effects of reducing both salt
and SFA intake simultaneously, considered here.
Strengths of the study
A strength of this study is that cardiovascular risk factors,
dietary habits and nutrient intake of the Finnish population
aged 30–74 years were obtained from a well-characterised
and representative sample of Finnish adults (Paturi et al.,
2008; Peltonen et al., 2008), and the cost and quality of life
estimates were obtained from representative studies.
In the analysis, the independent role of dietary salt
reduction of 1g was larger than the role of a 1 E% change
of SFA to PUFA. This is because both the effect sizes obtained
from the literature differ and also the b-coefficients of
FINRISK functions for the association of SBP with both
CVD events and deaths are more significant than for the
Table 2 Predicted cumulative health and economic changes compared the situation in year 2007 between the years 2010 and 2030
Scenario 2010 Difference (95% CrI) 2020 Difference (95% CrI) 2030 Difference (95% CrI)
Base case (salt  1g, SFA  1 E%, PUFA þ1E % )
Non-fatal CVD  215 ( 348 to  97)  2502 ( 2944 to  2088)  4752 ( 5336 to  4185)
Fatal CVD  137 ( 296 to  60)  1684 ( 1980 to  1395)  3271 ( 3662 to  2897)
Cost (1000h)
With productivity losses  6786 ( 11506 to  2 926)  70507 ( 84489 to  57924)  147094 ( 167364 to  128731)
Without productivity losses  5916 ( 10057 to  2 610)  62339 ( 75200 to  50533)  130404 ( 147707 to  113397)
QALYs gained 1105 (438 to 2 059) 13444 (10699 to 16434) 26255 (22498 to 30102)
Base case with the Keys equation
Non-fatal CVD  341 ( 551 to  172)  3930 ( 4 612 to  3 286)  7448 ( 8372 to  6611)
Fatal CVD  236 ( 385 to  115)  2833 ( 3 298 to  2 363)  5470 ( 6152 to  4840)
Cost (1000h)
With productivity losses  10425 ( 17098 to  5 022)  107996 ( 127347 to  89659)  224785 ( 252792 to  197489)
Without productivity losses  8312 ( 13563 to  4 169)  88604 ( 105982 to  74291)  185784 ( 207850 to  164578)
QALYs gained 1907 (813 to 3409) 23232 (18723 to 28291) 45142 (38586 to 52421)
Sensitivity analysis
a
( 1.0g of salt,  0.0 E% SFA)
Cost with productivity losses (1000h)  6683  69923  146522
QALYs gained 1083 13363 26142
Baseline risk of CVD event is decreased by  10%
Cost with productivity losses (1000h)  6370  66830  139471
QALYs gained 1016 12480 24386
Baseline risk of CVD event is increased by þ10%
Cost with productivity losses (1000h)  7158  7389  153920
QALYs gained 1180 14345 27979
Abbreviations: CrI, credibility interval; CVD, cardiovascular disease; E%, energy percent; PUFA, polyunsaturated fat; QALYs, quality-adjusted life years; SFA, saturated
fat.
aOnly deterministic cost savings and QALYs gained are reported for one-way sensitivity analysis.
95% CrI are based on the Monte Carlo simulation.
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Figure 2 Probability of cumulative savings (with and without
productivity losses) given a dietary salt and saturated fat reduction of
1g and 1 E% per day (base case scenario) among Finnish adults
aged 30 to 74 between years 2010and 2030. PL¼productivity losses
included.
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is in part because serum TC is not included in the FINRISK
function that predicts the risk of stroke. In contrast, SBP is a
major risk factor for both stroke and MI. The analyses also
assume that dietary fat quality mediates its effects on CVD
risk solely via effects on lipids. However, dietary fat quality
may influence CVD risk by mechanisms other than choles-
terol (Erkkila ¨ et al., 2008), and the relatively strong inverse
associations of PUFA intake and the PUFA/SFA ratio with
coronary heart disease or CVD risk from some prospective
cohort studies (Hu et al., 1997; Laaksonen et al., 2005; Erkkila ¨
et al., 2008) also implies that dietary fat quality impact
cardiovascular risk more than would be predicted by effects
on the lipid profile alone.
This study focused on replacement of SFA with PUFA.
Because replacement of SFA with monounsaturated fat yields
similar effects on the lipid profile (Clarke et al., 1997), results
would have been similar if monounsaturated or other
unsaturated fat had been used in place of PUFA.
Limitations of the study
As the results of this study are based on statistical computer
modelling requiring several assumptions, the results should
be interpreted cautiously. This study did not specify any
particular intervention aiming to reduce the dietary salt
and SFA intake from daily food. However, the modest
reductions presented here could be achieved by voluntary
actions of the food industry aimed at a reducing the use of
salt and SFA in processed food, a major source of dietary salt
and SFA (Paturi et al., 2008). There are already examples
about successful strategies that have managed to reduce the
intake of salt and SFA in cooperation with the food industry
(Pra ¨tta ¨la, 2003; Laatikainen et al., 2006; Food Standard
Agency, 2008; Pietinen et al., 2008). These interventions,
for example, have managed to reduce the intake of salt
by 10–25% (Laatikainen et al., 2006; Food Standard
Agency, 2008).
We assumed no changes in consumer behaviour and
persistence associated with these modifications, and dra-
matic changes in consumer behaviour would be unlikely,
given that a reduction of dietary salt, for example, by
10–15% is possible without detection (Girgis et al., 2003;
Ruusunen and Puolanne, 2005). Moreover, after an adapta-
tion period people appear to prefer food with less salt (Blais
et al., 1986).
To ensure the robustness of the study results, the study
population was restricted to people aged 30–74 years.
However, 450% of CVD cases occurs among the population
aged X75 in Finland, so an important segment of the
Finnish population could not be modelled. The impact in
the whole population is, thus, clearly underestimated.
However, at the moment there are no epidemiological data
available to inform the association between CVD risk factors
and the risk of CVD events among the elderly in Finland.
The reduction of dietary salt and SFA is likely to benefit also
subjects aged o30 years, which will potentially decrease the
future prevalence of hypertension and hyperlipidaemia in
older age groups.
Moreover, there were no relevant estimates available for
the proportion of patients provided assisted care or care in
institutions such as nursing homes after non-fatal stroke or
MI. Therefore, the cost of institutionalisation, which is
especially important following stroke, has not been con-
sidered in the analysis. Also, potential changes in the
number of patients with heart failure, end-stage renal disease
or dementia (Kivipelto et al., 2006; Solomon et al., 2010)
were not considered in the analysis due to the lack of data.
This analysis assumes that CVD risk factors stay at the
same levels as they were in year 2007. However, if the
declining trend in the levels of CVD risk factors seen in
1972–2007 (Vartiainen et al., 2010) will continue unabated,
the burden of CVD may not increase as much as presented in
this study. On the other hand, the current epidemic of
obesity and type II diabetes may have a negative impact on
the trends seen in CVD incidence over the past several
decades (Poirier et al., 2006). Finally, the assumed linear
relationships between salt and SFA intakes and SBP and TC
may not hold, and there is evidence that reductions in BP
could be even greater at lower levels of salt intake (Sacks
et al., 2001). An underestimate of the true amount of future
cost savings and improved health at the population level
may thus have resulted from these modelling assumptions.
Conclusion
Our findings suggest that even a modest reduction of dietary
salt and replacement of SFA content with PUFA in food
products can substantially reduce the total burden of CVDs
in the adult Finnish population, with large cost savings from
the societal point of view. The aging of the Finnish
population may reinforce this impact.
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